2025
SJR Q3
JCR Q4 · 1
12 eşleşen makale
SCIE
Dergi ayrıntısı
AIDS Research and Human Retroviruses
- Yayıncı
- Mary Ann Liebert Inc.
- Ülke
- United States · Northern America
- Tür
- journal
- ISSN
-
0889222919318405
Bütünleşik değerlendirme
Scopus tarafı Scimago SJR; WoS tarafı Master Journal List + JCR/JIF. Kaynaklar ISSN üzerinden eşleştirilir. WoS / JCR metrikleri yalnızca 1997 ve sonrası yıllar için vardır.
WoS / JCR verileri 1997 ve sonrası içindir.
Scopus
Scopus · Scimago
- SJR 0,516
- Quartile Q3
- H-Index 100
- Atıf/yayın 1,32
- Doküman (3y) 288
- Atıf (3y) 412
Clarivate
Web of Science · JCR · 2025
- JCR Q Q4
- JIF 1
- 5Y JIF 1,3
- JCI 0,31
WoS indeksleri
- SCIE
Konu sınıflandırması
Kategoriler (SJR)
- Immunology Q3
- Infectious Diseases Q3
- Virology Q3
Alanlar
- Immunology and Microbiology
- Medicine
WoS kategorileri
- Immunology | Infectious Diseases | Virology
Yıllık quartile karşılaştırması
Scimago (SJR) tüm yıllar; Clarivate (JCR / JIF / JCI) 1997 ve sonrası. Güncel yıl açık; diğer yıllar kapalıdır.
WoS / JCR verileri 1997 ve sonrası içindir.
| Yıl | SJR Q | JCR Q (1997+) | SJR | JIF (1997+) | 5Y JIF (1997+) | JCI (1997+) | JCI Q (1997+) | H-Index |
|---|---|---|---|---|---|---|---|---|
| 2025 | Q3 | Q4 | 0,516 | 1 | 1,3 | 0,31 | Q4 | 100 |
| 2024 | Q3 | Q4 | 0,554 | 1,1 | 1,3 | 0,32 | Q4 | 99 |
| 2023 | Q3 | Q4 | 0,542 | 1,5 | 2,1 | 0,28 | Q4 | 99 |
| 2022 | Q3 | Q4 | 0,562 | 1,5 | 1,6 | 0,31 | Q4 | 99 |
| 2021 | Q2 | Q4 | 0,64 | 1,7 | 1,8 | 0,35 | Q4 | 99 |
| 2020 | Q2 | Q4 | 0,993 | 2,2 | 2,1 | 0,52 | Q3 | 99 |
| 2019 | Q2 | Q4 | 0,988 | 1,8 | 1,8 | 0,54 | Q3 | 99 |
| 2018 | — | Q3 | — | 1,8 | 1,7 | 0,51 | Q3 | — |
| 2017 | Q2 | Q3 | 1,066 | 1,9 | 1,9 | 0,53 | Q3 | 99 |
| 2016 | Q2 | Q3 | 1,07 | 2,1 | 1,9 | — | — | 99 |
| 2015 | Q2 | Q3 | 1,091 | 1,9 | 1,8 | — | — | 99 |
| 2014 | Q1 | Q3 | 1,253 | 2,3 | 2,2 | — | — | 99 |
| 2013 | Q1 | Q3 | 1,194 | 2,5 | 2,2 | — | — | 99 |
| 2012 | Q1 | Q2 | 1,17 | 2,7 | 2,4 | — | — | 99 |
| 2011 | Q2 | Q3 | 1,18 | 2,2 | 2,1 | — | — | 99 |
| 2010 | Q2 | Q3 | 1,207 | 2,1 | 2 | — | — | 99 |
| 2009 | — | Q3 | — | 2,2 | 2,2 | — | — | — |
| 2008 | — | Q3 | — | 2 | 2,1 | — | — | — |
| 2007 | — | Q3 | — | 2 | 2,3 | — | — | — |
| 2006 | — | Q2 | — | 2,5 | — | — | — | — |
| 2005 | — | Q2 | — | 2,5 | — | — | — | — |
| 2004 | — | Q2 | — | 2,4 | — | — | — | — |
| 2003 | — | Q2 | — | 2,3 | — | — | — | — |
| 2002 | — | Q2 | — | 2,3 | — | — | — | — |
| 2001 | — | Q2 | — | 2,5 | — | — | — | — |
| 2000 | — | Q1 | — | 2,9 | — | — | — | — |
| 1999 | — | Q2 | — | 2,5 | — | — | — | — |
| 1998 | — | Q1 | — | 2,6 | — | — | — | — |
| 1997 | — | Q1 | — | 3,1 | — | — | — | — |
JCR kategori quartile geçmişi
Yıla ve kategoriye göre JCR / JCI quartile. 1997 ve sonrası.
WoS / JCR verileri 1997 ve sonrası içindir.
| Yıl | Kategori | Edition | JCR Q (1997+) | JCI Q (1997+) | Sıra |
|---|---|---|---|---|---|
| 2025 | IMMUNOLOGY | SCIE | Q4 | Q4 | 173/183 |
| 2025 | INFECTIOUS DISEASES | SCIE | Q4 | Q4 | 127/141 |
| 2025 | VIROLOGY | SCIE | Q4 | Q4 | 41/44 |
| 2024 | IMMUNOLOGY | SCIE | Q4 | Q4 | 168/183 |
| 2024 | INFECTIOUS DISEASES | SCIE | Q4 | Q4 | 117/137 |
| 2024 | VIROLOGY | SCIE | Q4 | Q4 | 38/42 |
| 2023 | IMMUNOLOGY | SCIE | Q4 | Q4 | 154/181 |
| 2023 | INFECTIOUS DISEASES | SCIE | Q4 | Q4 | 104/132 |
| 2023 | VIROLOGY | SCIE | Q4 | Q4 | 35/41 |
| 2022 | IMMUNOLOGY | SCIE | Q4 | Q4 | 149/161 |
| 2022 | INFECTIOUS DISEASES | SCIE | Q4 | Q4 | 88/96 |
| 2022 | VIROLOGY | SCIE | Q4 | Q4 | 33/36 |
| 2021 | IMMUNOLOGY | SCIE | Q4 | Q4 | 152/162 |
| 2021 | INFECTIOUS DISEASES | SCIE | Q4 | Q4 | 86/95 |
| 2021 | VIROLOGY | SCIE | Q4 | Q4 | 34/37 |
| 2020 | IMMUNOLOGY | SCIE | Q4 | Q4 | 142/162 |
| 2020 | INFECTIOUS DISEASES | SCIE | Q4 | Q3 | 75/93 |
| 2020 | VIROLOGY | SCIE | Q4 | Q4 | 31/37 |
| 2019 | IMMUNOLOGY | SCIE | Q4 | Q3 | 134/159 |
| 2019 | INFECTIOUS DISEASES | SCIE | Q4 | Q3 | 74/92 |
| 2019 | VIROLOGY | SCIE | Q4 | Q3 | 30/37 |
| 2018 | IMMUNOLOGY | SCIE | Q4 | Q4 | 133/158 |
| 2018 | INFECTIOUS DISEASES | SCIE | Q4 | Q3 | 71/89 |
| 2018 | VIROLOGY | SCIE | Q3 | Q3 | 27/36 |
| 2017 | IMMUNOLOGY | SCIE | Q4 | Q3 | 128/155 |
| 2017 | INFECTIOUS DISEASES | SCIE | Q3 | Q3 | 64/88 |
| 2017 | VIROLOGY | SCIE | Q3 | Q3 | 26/35 |
| 2016 | IMMUNOLOGY | SCIE | Q4 | — | 115/151 |
| 2016 | INFECTIOUS DISEASES | SCIE | Q3 | — | 58/84 |
| 2016 | VIROLOGY | SCIE | Q3 | — | 22/34 |
| 2015 | IMMUNOLOGY | SCIE | Q4 | — | 118/151 |
| 2015 | INFECTIOUS DISEASES | SCIE | Q3 | — | 56/83 |
| 2015 | VIROLOGY | SCIE | Q3 | — | 24/33 |
| 2014 | IMMUNOLOGY | SCIE | Q3 | — | 97/148 |
| 2014 | INFECTIOUS DISEASES | SCIE | Q3 | — | 48/78 |
| 2014 | VIROLOGY | SCIE | Q3 | — | 21/33 |
| 2013 | IMMUNOLOGY | SCIE | Q3 | — | 84/144 |
| 2013 | INFECTIOUS DISEASES | SCIE | Q3 | — | 41/72 |
| 2013 | VIROLOGY | SCIE | Q3 | — | 19/33 |
| 2012 | IMMUNOLOGY | SCIE | Q3 | — | 76/137 |
| 2012 | INFECTIOUS DISEASES | SCIE | Q2 | — | 31/70 |
| 2012 | VIROLOGY | SCIE | Q2 | — | 17/34 |
| 2011 | IMMUNOLOGY | SCIE | Q3 | — | 97/139 |
| 2011 | INFECTIOUS DISEASES | SCIE | Q3 | — | 42/70 |
| 2011 | VIROLOGY | SCIE | Q3 | — | 21/32 |
| 2010 | IMMUNOLOGY | SCIE | Q3 | — | 93/134 |
| 2010 | INFECTIOUS DISEASES | SCIE | Q3 | — | 41/58 |
| 2010 | VIROLOGY | SCIE | Q3 | — | 22/33 |
| 2009 | IMMUNOLOGY | SCIE | Q3 | — | 88/128 |
| 2009 | INFECTIOUS DISEASES | SCIE | Q3 | — | 34/57 |
| 2009 | VIROLOGY | SCIE | Q3 | — | 19/30 |
| 2008 | IMMUNOLOGY | SCIE | Q3 | — | 85/121 |
| 2008 | INFECTIOUS DISEASES | SCIE | Q3 | — | 37/51 |
| 2008 | VIROLOGY | SCIE | Q3 | — | 18/27 |
| 2007 | IMMUNOLOGY | SCIE | Q3 | — | 81/119 |
| 2007 | INFECTIOUS DISEASES | SCIE | Q3 | — | 31/50 |
| 2007 | VIROLOGY | SCIE | Q3 | — | 17/25 |
| 2006 | IMMUNOLOGY | SCIE | Q3 | — | 59/117 |
| 2006 | INFECTIOUS DISEASES | SCIE | Q2 | — | 20/47 |
| 2006 | VIROLOGY | SCIE | Q3 | — | 16/23 |
| 2005 | IMMUNOLOGY | SCIE | Q2 | — | 52/115 |
| 2005 | INFECTIOUS DISEASES | SCIE | Q2 | — | 18/43 |
| 2005 | VIROLOGY | SCIE | Q3 | — | 16/23 |
| 2004 | IMMUNOLOGY | SCIE | Q2 | — | 49/111 |
| 2004 | INFECTIOUS DISEASES | SCIE | Q2 | — | 14/41 |
| 2004 | VIROLOGY | SCIE | Q3 | — | 13/22 |
| 2003 | IMMUNOLOGY | SCIE | Q2 | — | 49/114 |
| 2003 | INFECTIOUS DISEASES | SCIE | Q2 | — | 12/41 |
| 2003 | VIROLOGY | SCIE | Q3 | — | 13/23 |
| 2002 | IMMUNOLOGY | SCIE | Q2 | — | 52/119 |
| 2002 | INFECTIOUS DISEASES | SCIE | Q2 | — | 14/38 |
| 2002 | VIROLOGY | SCIE | Q3 | — | 14/24 |
| 2001 | IMMUNOLOGY | SCIE | Q2 | — | 41/114 |
| 2001 | INFECTIOUS DISEASES | SCIE | Q2 | — | 12/37 |
| 2001 | VIROLOGY | SCIE | Q2 | — | 10/25 |
| 2000 | IMMUNOLOGY | SCIE | Q1 | — | 28/116 |
| 2000 | INFECTIOUS DISEASES | SCIE | Q2 | — | 11/36 |
| 2000 | VIROLOGY | SCIE | Q2 | — | 11/28 |
| 1999 | IMMUNOLOGY | SCIE | Q2 | — | 35/115 |
| 1999 | INFECTIOUS DISEASES | SCIE | Q2 | — | 11/35 |
| 1999 | VIROLOGY | SCIE | Q2 | — | 8/26 |
| 1998 | IMMUNOLOGY | SCIE | Q1 | — | 27/120 |
| 1998 | INFECTIOUS DISEASES | SCIE | Q1 | — | 8/36 |
| 1998 | VIROLOGY | SCIE | Q1 | — | 6/25 |
| 1997 | IMMUNOLOGY | SCIE | Q1 | — | 20/117 |
| 1997 | INFECTIOUS DISEASES | SCIE | Q1 | — | 5/34 |
| 1997 | VIROLOGY | SCIE | Q1 | — | 6/24 |